Tryp Therapeutics Information, Including Revenue, Investors, Funding, Competitors & Key Metrics

Tryp Therapeutics is a pharmaceutical company focused on developing compounds with known activity and/or safety profiles for the treatment of rare diseases and other diseases with high unmet medical needs. Tryp's psilocybin-for-neuropsychiatric disorders, or PFN™, program is focused on the development of synthetic psilocybin as a new class of drug for the treatment of certain neuropsychiatric-based disorders.

Company Highlights
Year Founded

2019

icon-altEmployees

10

Location (HQ)

AUS

Since Last Funding

1 year 2 months

Monthly Website Visitors

1.3K

icon-altTotal Investment Amt

$11M

Last Funding Round

Post Ipo Equity

Key Metrics

Senior Hires

NameLinkedin ProfilePositionDate Joined
John Doehttps://www.linkedin.com/in/johndoeCEOCEO
Jane Doehttps://www.linkedin.com/in/janedoeCTOCTO
John Smithhttps://www.linkedin.com/in/johnsmithCFOCFO
Jane Smithhttps://www.linkedin.com/in/janesmithCOOCOO
Get API access to complete private company database with growth metrics from 15 sources

Biotechnology Research

Biotechnology